Characteristics of patients with HGBL vs non-HGBL at the date of infusion
| Infusion, n = 195 (86%) . | P value . | ||
|---|---|---|---|
| Characteristic | HGBL, n = 60 (82.2%) | Non-HGBL, n = 135 (87.1%) | .322 |
| Age, median (range), y | 61.5 (26-78) | 62 (17-80) | .590 |
| Bulky disease, >5 cm, n (%) | 16 (26.7) | 34 (25.2) | .859 |
| ECOG ≥2, n (%) | 11 (18.3) | 20 (14.8) | .670 |
| Elevated LDH, >1N, n (%) | 37 (61.7) | 76 (56.3) | .702 |
| CRP >30 mg/L, n (%) | 16 (26.7) | 31 (23) | .379 |
| Bridging therapy, n (%) | 55 (91.7) | 126 (93.3) | .765 |
| Response after bridging, n (%) | .378 | ||
| CR/PR | 19 (34.5) | 46 (36.5) | |
| SD/PD | 34 (61.8) | 79 (62.7) | |
| CAR T-cell product, n (%) | .518 | ||
| Axi-cel | 37 (61.7) | 90 (66.7) | |
| Tisa-cel | 23 (38.3) | 45 (33.3) | |
| Infusion, n = 195 (86%) . | P value . | ||
|---|---|---|---|
| Characteristic | HGBL, n = 60 (82.2%) | Non-HGBL, n = 135 (87.1%) | .322 |
| Age, median (range), y | 61.5 (26-78) | 62 (17-80) | .590 |
| Bulky disease, >5 cm, n (%) | 16 (26.7) | 34 (25.2) | .859 |
| ECOG ≥2, n (%) | 11 (18.3) | 20 (14.8) | .670 |
| Elevated LDH, >1N, n (%) | 37 (61.7) | 76 (56.3) | .702 |
| CRP >30 mg/L, n (%) | 16 (26.7) | 31 (23) | .379 |
| Bridging therapy, n (%) | 55 (91.7) | 126 (93.3) | .765 |
| Response after bridging, n (%) | .378 | ||
| CR/PR | 19 (34.5) | 46 (36.5) | |
| SD/PD | 34 (61.8) | 79 (62.7) | |
| CAR T-cell product, n (%) | .518 | ||
| Axi-cel | 37 (61.7) | 90 (66.7) | |
| Tisa-cel | 23 (38.3) | 45 (33.3) | |
1N, normal range; CRP, C-reactive protein; PD, progressive disease; PR, partial response; SD, stable disease.